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ABSTRACT 
Objective: This work was aimed at formulating artesunate tablets with hydroxypropyl methylcellulose (HPMC)-a hydrophilic polymer for the 
purpose of achieving a sustained release profile of the drug and evaluating their properties. 
Methods: The solubility profile of artesunate was determined in water, methanol, ethanol, ethanol/water mixtures (50/50, 40/60 v/v), simulated 
intestinal fluid (SIF) without enzymes (pH 7, 7.2 and 8), simulated gastric fluid (SGF) without enzymes (pH 1.2), 0.1N hydrochloric acid (HCI), 0.1N 
sodium hydroxide (NaOH), 0.1N acetic acid and phosphate buffer solution, PBS (pH 7, 7.2 and 8). Four batches of oral sustained release artesunate 
tablets intended for once-daily dosing were formulated with 10%, 20%, 25% and 30% w/w concentrations of HPMC using wet granulation method. 
Evaluation of granule properties was done by determining the angle of repose, flow rate, bulk density, tapped density, Carr’s index and Hausner’s 
quotient. The compressed tablets were also evaluated using official and non-official parameters. Absolute drug contents were determined in 0.1N 
NaOH, ethanol and methanol. In vitro release was studied in different media and release kinetics mechanism elucidated. In vivo studies were carried 
out using healthy Wistar rats.  
Results: Artesunate was observed to exhibit solubility at varying degrees depending on solvents or media employed as well as the pH of the media. All 
the granule batches have Hausner’s quotient value of approximately 1.2. The values for Carr’s index for all the batches ranged between 30 and 40. The 
angle of repose, Carr’s index and Hausner’s quotient values indicate good flow properties of the granules for all the batches. All the tablet batches 
conformed to official standard in terms of weight uniformity as no single tablet deviated beyond 5% from the average weight in each batch with no 
significant difference in the values (p>0.05). Values of hardness increased insignificantly from batches A to D (p>0.05). Friability values were very low 
and follows no specific pattern among the batches but the difference in the values was significant (p<0.05). Absolute drug content reduced while in vitro 
release times increased as hardness increased, indicating the probable progressive reduction in the tendency of the matrix to release the drug as the 
concentration of HPMC increased from batches A to D. n values obtained from analysis of release mechanism were above 0.89 for each batch. 
Conclusion: The release mechanism was shown to be complex and the release involved zero order, first order, and Higuchi model kinetics. The 
biological half-life of artesunate was shown to be 1.05 hr, and metabolites which bear resemblance to artesunate in absorbance seem to be 
encountered. In this work, HPMC matrix yielded high-quality tablets indicating its usefulness in sustained released product development. 
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INTRODUCTION 
Post-1990 is the modern era of controlled release technology-the 
period in which an attempt at drug delivery optimization is 
emphasized [1]. Over the years, pharmaceutical dosage delivery 
researchers and developers have focused on approaches to arrive at 
more convenient, more effective and more reliable dosage delivery 
systems that enhance drug performance over and above the 
conventional ones [2]. The concept of sustained release formulation 
was developed to eliminate the need for multiple dosage regimens, 
particularly for those drugs requiring reasonably constant blood 
levels over a long period of time. In addition, it also has been 
adopted for those drugs that needed to be administered in high 
doses but where too rapid a release is likely to cause undesirable 
side effects [3].
HPMC is a cellulose derivative chemically known as cellulose 
hydroxypropyl methyl ether. It is soluble in different solvents and 
their mixtures [4] and is widely used in oral and topical 
pharmaceutical formulations. In oral products, it is primarily used as 
tablet binder [5]. Depending upon the viscosity grade, 
concentrations between 2-20% w/w are used as film coating 
solutions in film-coated tablets. Lower viscosity grades are 
employed in aqueous film coating solutions while higher viscosity 
grades are used with organic solvents. Thus, in oral products, HPMC 
is used in film coating of tablets [6]. Cellulose ethers are often 
preferred polymers in film coating, particularly HPMC, although 
these polymers have been reported to retard drug dissolution [3, 4].  
 For some drugs, the incidence of side effects as well 
as toxicity is believed to be a function of plasma concentration [1]. 
HPMC is usually employed as tablet binder at concentrations 
between 2-5% w/w in either wet or dry granulation process. High 
viscosity grades may be used to retard the release of drugs from a 
matrix at levels 10-80% w/w in tablets and capsules. It is also used 
as a binder in capsule manufacture, adhesive in plastic bandages, a 
wetting agent for contact lenses, pharmaceutical emulsifier, a 
suspending agent in topical gels and ointment, and as adjuvants in 
cosmetics and food products. 
Artestunate is a white crystalline powder with a melting point 
between 132-135 °C and is slightly soluble in water [7]. The drug is a 
hemi succinate derivative of dihydroartemisinin employed as an 
anti-plasmodial agent. Artemisinin is a sequiterpene lactone isolated 
form Artemisia anua, a herb that has traditionally been used in China 
for the treatment of malaria [8]. It has a biological half-life of less 
than two hours. Artesunate was thus in this research work 
formulated as sustained release tablet to remedy the difficulties 
associated with frequent dosing and to prevent the development of 
drug resistance.  
This work was aimed at digging deeper into artesunate to generate 
information that would help stakeholder professionals-health care 
providers, researchers as well as manufacturers. It is also designed 
to establish and develop a simple convenient and reliable spectro-
photometric method of assay for artesunate, and to study the release 
pattern in different concentrations of a polymer matrix and 
determine the suitability of the artesunate tablet formulation as oral 
sustained release delivery system of the drug.  
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MATERIALS AND METHODS 
Materials 
Materials used were artesunate powder (Emzor Pharmaceutical 
Limited, Nigeria), HPMC (Shi-Etsu, France), lactose (May and Baker, 
England), stearic acid (May and Baker, England), absolute ethanol 
(Sigma-Aldrich, Germany), hydrochloric acid (May and Baker, 
England), acetic acid (BDH, England), monobasic potassium 
phosphate (Sigma-Aldrich, Germany), sodium dihydrogen phosphate 
monohydrate (Sigma-Aldrich, Germany), anhydrous disodium 
hydrogen phosphate (Sigma-Aldrich, Germany), methanol (Sigma-
Aldrich, Germany). Other materials used in the analysis and 
evaluation of the tablets were of analytical grade. 
Preparation of dissolution media 
SGF without enzymes was prepared by adding 42.4 ml of 
concentrated HCl (36.5%) to 2.0 l of distilled water. To this was 
added 10 g of sodium chloride and mixed until complete dissolution 
occurred. The solution was made up to 5.0 l with distilled water. SIF 
without enzymes was prepared by dissolving 40 g of NaOH in 
distilled water and 34 g of monobasic potassium phosphate was 
added to obtain solutions of pH 7, 7.2 and 8. A 4 g quantity of NaOH 
was added to 100 ml of distilled water. Stock A of PBS was prepared 
by adding 27.6 g of sodium dihydrogen phosphate monohydrate to 
1000 ml of distilled water. Stock B was prepared by adding 28.3 g of 
anhydrous disodium hydrogen phosphate to 1000 ml of distilled 
water. A 200 ml volume of pH 8 was prepared by adding 8.3 ml of 
stock A and 91.7 ml of stock B to 100 ml of distilled water. Also, 200 
ml volume of pH 7.2 was prepared by adding 28 ml of stock A and 72 
ml of stock B to 100 ml of distilled water. Similarly, 200 ml volume 
of pH 7 was prepared by adding 39 ml of stock A and 61 ml of stock 
B to 100 ml of distilled water. An 8.5 ml volume of concentrated HCl 
(36.8% purity and 1.18 g/ml specific gravity) was added into 1000 
ml of distilled water. 
Solubility profile of artesunate 
The degree of solubility of artesunate was determined in water, 
methanol, ethanol (96%), ethanol/water mixtures (50/50, 40/60 
v/v), SIF (pH 7, 7.2, 8), SGF (pH 1.2), 0.1N HCl, 0.1N NaOH, 0.1N 
acetic acid, and PBS (pH 7, 7.2, 8). This was done by adding 50 mg of 
artesunate into a volume of 100 ml of individual medium and 
allowing it to stand for 3 h. It was then filtered with pre-weighed 
filter paper, which was dried after and the amount dissolved 
calculated by difference. This was repeated twice for each medium 
and the average in each case obtained. 
Beer’s plot  
A spectrophotometric scan of 100 mg % of artesunate solution in 
ethanol, 0.1N NaOH, 0.1N acetic acid, methanol, SIF, SGF, 
serum/NaOH mixture and alcohol/water mixture was carried out 
and wavelengths of peak absorbance were obtained in each medium. 
The plot of absorbance against concentration (Beer’s plot) in each 
medium was then made. 
Preparation of artesunate granules  
Four batches of artesunate granules were prepared by non-aqueous 
wet granulation method to avoid unwanted swelling of HPMC which 
could occur in granulation fluid. Therefore, ethanol/water mixture 
was employed (50/50 w/w). HPMC was incorporated at the 
concentrations of 10 %, 20 %, 25 % and 30 % of the tablet weight. 
Appropriate quantities of artesunate and lactose powders were 
thoroughly mixed. The mixed powders were wet-massed with HPMC 
paste to form a homogenous adhesive damp mass. The wet mass 
was passed through sieve no. 10 (17 mm) and dried in hot air oven 
at 50 °C for one hour. The dried granules were then passed through 
sieve no. 16 (1.0 mm). The dried granules were characterized before 
compression. The formulae for all the batches are shown in table (1).
 
Table 1: Formula for preparation of artesunate tablets formulated with various concentrations of HPMC 
 Batch A* Batch B* Batch C* Batch D* 
Artesunate (mg) 450 450 400 400 
HPMC (mg) 60 120 150 180 
Lactose (mg) 78 18 38 8 
Stearic acid (mg) 12 12 12 12 
Total (mg) 600 600 600 600 
*Batches A, B, C and D were formulated with 10 %, 20 %, 25 % and 30 % of HPMC, respectively 
 
The dose of artesunate incorporated into each tablet of batches A 
and B was determined by calculation as presented below:  
𝑆𝑆𝑆𝑆 = ℎ𝑘𝑘𝑆𝑆 + (𝑆𝑆–𝑅𝑅𝑅𝑅𝑅𝑅)…………. (1) 
Where SD is sustained release dose, h = desired duration of release = 
12 h, R = availability rate = 35 mg/h = KD, k = elimination rate 
constant = 0.693/t1/2, D = initial dose = 100 mg, t1/2 = biological half = 
2 h, and tp = time for peak plasma level = 2h. 
For batches, C and D, the typical administration dose of a drug in the 
conventional dosage form will give some indication of the total amount 
needed in the controlled release preparation 200 mg b. i. d = 400 mg. 
Determination of some flow and density properties 
The angle of repose (the maximum angle possible between the 
surface of a heap of powder and the horizontal plane) [9], flow rate, 
bulk and tapped densities, Carr’s and Hausner’s quotients [10] were 
all determined for each batch. A mean of three readings was then 
taken for each determined parameter. 
Preparation and evaluation of artesunate matrix tablets 
The artesunate granules of batches A to D were compressed on an 
F3 Manesty single punch tabletting machine (Manesty England) at a 
constant compression load of 50 kN. The performance of the 
compressed tablets was evaluated by employing hardness test, 
uniformity of weight, content uniformity, friability test, and absolute 
drug content and release studies [11, 12]. 
Weight variation  
Twenty tablets were randomly selected from each batch and weighed 
individually. The mean weights and percentage deviation were 
calculated and recorded. This was done according to USP [12, 13] 
Friability test  
Ten tablets from each batch were used and method reported by 
various workers was employed [12, 14-16]. The tablets were dusted, 
weighed (wi) and put in Erweka model friabilator (Roche, England). 
The friabilator was operated for 4 min at 25 rpm. The tablets were 
then brought out, dusted and reweighed and the final weights (wf) 
recorded. Friability (B) was calculated as a percentage weight loss 
using the equation below:  
B = 100. wi − wf
wi
 …………. (2) 
Values in the range of 0.8-1 % are frequently quoted as the upper 
level of acceptance for pharmaceutical products or up to 20 % for 
directly compressed products [14]. 
Tablet strength 
Mosanto hardness tester (Manesty, England) was used to determine 
the hardness of the tablets [16] by noting the load or pressure 
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required to crush each tablet. Ten tablets were used in each batch. 
The tablet was placed between the anvil and plunger. Pressure was 
then applied to the tablet via the plunger by means of a screw until 
the tablet fractured and the crushing strength read and recorded. 
Absolute drug content and content uniformity 
Method recorded by Bhosale et al. was modified and employed [16]: 
Five tablets from each batch were weighed and their mean weighed 
obtained. They were then crushed and a quantity each equivalent to 
the mean weight was weighed and dissolved in 900 ml of ethanol; 
900 ml of 0.1N NaOH and 900 ml of methanol. The values of 
absorbance were taken after dilution at 288 nm, 237 nm and 222 nm 
in 0.1N NaOH, ethanol and amounts of the drug were calculated with 
reference to their respective Beer’s plots. Twenty tablets from each 
batch were individually assayed spectrophotometrically in 0.1N 
NaOH and ethanol. 
Dissolution and release studies 
In vitro studies 
In vitro release of artesunate was determined in 0.1N NaOH, SGF, SIF 
and ethanol/water mixture for the four batches of the tablets using a 
standard United States pharmacopoeia rotating paddle apparatus 
(method II) (Erweka, Germany) [13, 17-19]. A 900 ml of the 
dissolution medium was to ensure sink condition at 50 rpm. The 
dissolution experiment was carried out at 37±1 °C. At each 
predetermined time interval, 5 ml sample was withdrawn and 
replaced with the fresh dissolution medium. The samples withdrawn 
were diluted appropriately after filtration and the absorbance values 
determined at their individual wavelengths followed by 
concentrations and amounts determination. Release profiles of the 
different batches were plotted and T30%, T50%, T70% and Cmax evaluated. 
From the data obtained, in vitro release kinetics was then 
investigated using the following models: Zero order, First order, 
Higuchi and Korsmeyer equations. 
In vivo studies  
Healthy Wistar albino rats of either sex weighing between 200 and 
210 g, used for this study were maintained at housing conditions of 
24±2 °C temperature and 55% relative humidity with 12 h light. The 
animals were fed with a commercial diet and potable water provided 
ad libitum throughout the study. Official permission for the animal 
experimental procedures was granted by the Ethics Committee of 
Faculty of Pharmacy, University of Uyo, Uyo, Nigeria (approval number 
UU/PH/006) and in conformity with the Federation of European 
Laboratory Animal Science Association and the European Community 
(Council Directive 86/609/EEC) of 1986 [20] 
Calculated quantities of the drug were administered to four batches 
of rats at 125 mg/kg. Artesunate tablets were prepared as 
suspension and administered orally using appropriate oral dosing 
needles. The suspension was administered within 5 min of 
preparation. Blood samples were collected at a predetermined time 
interval and the serum obtained was analyzed spectro-
photometrically after appropriate dilution with 0.1N NaOH and 
filtration at 280 nm. 
The AUC, t1/2 for the first four hours and Cmax, were calculated using 
the trapezoid represented by:  
 
Where tn = higher time interval of drug concentration Cn tn-1 = lower 
time interval for drug concentration Cn-1  
t½ =0.693K  …………. (4) 
K calculated from  
Log Cp = Log Cpo– Kt2.303…………. (5) 
Cpo and Cp are plasma concentrations of the drug at the beginning 
and end of the time interval respectively. 
RESULTS AND DISCUSSION 
Artesunate was shown to be readily soluble in ethanol, methanol 
and 50/50 (V/V) ethanol/water mixture. It was also soluble 0.1N 
NaOH and 0.1N acetic acid in the degrees as indicated in table (2). 
The observed solubility of artesunate in SIF is contrary to what was 
recorded in an earlier work [21]. This could be attributed to possible 
polymorphic behaviour or crystalline and amorphous behaviour. A 
polymorph is a solid material with at least two different molecular 
arrangements each of which gives a distinct crystal species. There 
are also large differences in their physical properties so that they 
behave as distinct chemical entities. Solubility, melting point, 
density, crystal shape, optical and electrical properties and vapour 
pressure are often very different for each polymorph. Unfortunately, 
artesunate has not been analyzed against the backdrop of 
polymorphism and these differences in solubility may have far-
reaching effects on its pharmacokinetics and pharmacodynamics. It 
is also possible that the two types of artesunate are different salts. 
From Beer’s plots, values of absorbance A of artesunate in various 
media are: SIF (pH 7.2) A= 0.0013 C at 220 nm, SGF (pH 1.2) A = 
0.009 C at 253 nm, 0.1N NaOH A 0.0212 C at 288 nm, NaOH/serum A 
= 0.007 C at 288 nm, acetic acid A = 0.023 C at 219 nm, 
ethanol/water 50/50 v/v, A = 0.0122 C at 216 nm, methanol A 
0.0027 C at 222 nm, ethanol A = 0.003 C 237 nm. The wavelength of 
maximum absorption for the two types of artesunate are 287 nm 
and 288 nm which indicates that the two types may have the same 
chromophore.
  
Table 2: Solubility of artesunate in different media 
Media 
Water Methanol Ethanol Ethanol/water 
50/50 v/v 
Ethanol/water 
40/60 v/v  
SIF
(pH 
7.0) 
a SIF
(pH 
7.2) 
a SIFa
(pH 
8.0) 
  SGFb 0.1N 
HCl
 
(pH 1.2) 
0.1N 
NaOHc 
0.1N 
acetic 
acid 
d 
PBSe PBS 
(pH 7) (pH 
7.2) 
e PBSe (pH 
8) 
Solubility (%) 
26.0±1.3 100.0±3.5 100.0±3.1  96.0±3.3 20.0±1.1 6.0±1.1 6.6±1.3 8.0±1.2 20.0±1.0 21±1.0 70.0±1.0 70.0±1.0 0.0±0.0 3.0±0.2 4.0±0.4 
Values are shown as mean±SD, n = 3, aSIF: simulated intestinal fluid, bSGF: simulated gastric fluid, cHCl: hydrochloric acid, dNaOH: sodium hydroxide, 
ePBS: phosphate buffer solution  
 
 
Table 3: Some micromeritic properties of the artesunate granules 
Batch  Bulk density (g/cm3)  Tapped density (g/cm3)  Hausner’s ratio Flow rate (g/s)  Carr’s index Angle of repose (%)  
A 0.48±0.01 0.56±0.008 1.17±0.05 3.38±0.15 14.28±0.81 33.71±1.77 
B 0.47±0.01 0.53±0.010 1.14±0.04 3.35±0.18 12.08±1.16 34.57±1.39 
C 0.47±0.00 0.55±0.010 1.17±0.06 3.16±0.15 14.55±1.21 30.03±2.15 
D 0.45±0.02 0.50±0.010 1.11±0.02 3.17±0.16 10.35±1.09 30.03±1.95 
Values are shown as mean±SD, n = 3 
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From the micromeritic table (table 3), batch D exhibited excellent 
flow while batches, A, B and C had good flow. The better flowability 
of batch D could be attributable to its high concentration of HPMC as 
a binder in granulation. 
Hausner found out that the ratio of tapped density to bulk density 
was related to the inter-particulate friction and as such could be 
used to predict the flow of granules. Less cohesive granules such as 
coarse spheres have ratios of approximately 1.2, whereas more 
cohesive less free-flowing powders such as flakes has Hausner’s 
ratio greater than 1.6. From the above table, it could be seen that all 
the batches have Hausner’s ratio close to 1.2, which indicates their 
free-flowing batch and could still be attributable to its higher 
content of HPMC. 
According to Wells and Aulton [10], values of angle of repose less 
that 25 indicate excellent flow while values between 25 and 30 show 
good flow. Values between 30 and 40 indicate good flow that would 
be improved. However, the exact value of the angle of repose can 
depend on the method of measurement. The values in the table 
indicate good flow in all the batches and their values also lie within a 
close range. Lower angle of repose is widely known to correspond to 
higher flow of granules/powders. The values of angle of repose, 
Carr’s compressibility index and Hausner’s ratio corroborate the 
flow rate as presented in table (3). Generally, the values of each 
parameter within the batches were significantly different (p<0.05). 
The limits of acceptance or rejection of tablet batches based on the 
content of active ingredient or assay are usually presented in the 
individual drug monogram. 
Tables (4 to 7) show some of the properties of the tablets. All the 
batches were of good mechanical strength with low friability values 
indicating that they can withstand the stress associated with 
transportation, dispensing and storage processes. For friability, 
values in the range of 0.8–1% are frequently quoted as the upper 
level of acceptance for pharmaceutical products [13, 14]. Their 
values were not up to such limit and are perfectly acceptable. The 
individual weights of the tablets in each batch were fairly uniform. 
None of the tablets deviated up to 5% of the mean weight in each 
batch. Although the tablets weighed fairly uniformly, most of them 
deviated from the target weight of 600 mg which could be as a result 
of uneven die filling. Hardness values increased progressively as 
HPMC binder concentration increased (that is from batches A to D) 
with statistically insignificant difference in values (p>0.05). The values 
of friability were low but were significant (p<0.05) among the batches.
 
Table 4: Some properties of sustained release artesunate matrix tablets 
Batch Mean weight (mg)  Hardness (kgF)  Friability (%)  Absolute drug content (mg)  
A 594.00±12.26 7.70±0.54 0.29±0.013 345.00±4.04 
B  594.60±13.63  7.76±1.10 0.32±0.012 338.00±2.31 
C 593.20±14.50 8.20±1.10 0.28±0.008 305.33±9.01 
D 597.00±15.70 8.65±1.15 0.29±0.011 303.00±5.97 
Values are shown as mean±SD, n = 3 
 
All the batches performed fairly well in content uniformity. According 
to official books, when ten tablets are assayed individual, the batch 
fails to comply if more than one tablet is outside the range of 85 % to 
115 % of the average value or if any tablet is outside the range of 75 % 
to 125 % of the average [22]. Batch A as assayed in NaOH does not 
comply as they contain tablets with 130 % and 72 % releases. 
Batches A and D as assayed in ethanol have tablets outside the 
stipulated range. Batches B and C complied both as assayed in 0.1N 
NaOH and ethanol. Although most tablets in each of the batches 
were fairly uniform in terms of artesunate content, their mean 
values were all far from the labeled/target content strengths of 450 
mg and 400 mg of artesunate. It is also worthy of note that while the 
absolute drug content was fairly uniform in the batches, neither 
NaOH nor ethanol assay produced tablets of equal artesunate 
content as incorporated. Whereas tablets were of lower content as 
assayed in NaOH the values were higher with the assay in ethanol. 
The low values in the former could be attributed to the fact that 
artesunate, as shown in solubility profile, is only 70 % soluble in 
NaOH and absorption interference could be the reasons for higher 
values increase of ethanol and methanol as assay media. 
From fig. (1), batch D has the highest maximum percentage release 
followed by batch B. Batch C has the least maximum percent release. 
The times of 30 %, 50 % and 70 % release increased from batch A to 
batch D. This is in line with the increasing order of HPMC 
concentration. Batch D which has the highest HPMC of 30 %, HPMC 
has 6.25, 11, and 18 h for T30%, T50% and T70% respectively. Batch A 
which has the least concentration of HPMC recorded 1, 3, and 8 h for 
T30%, T50% and T70% respectively. Batch C did not release up to 70% of 
artesunate and as such has no value for T70%. Accordingly, all the 
batches sustained the release of artesunate according to their 
percentage content of HPMC. Cmax for all the batches was in a close 
range and around 70% as indicated in absolute drug content test 
and with regard to 70 % solubility of artesunate in 0.1N NaOH. For 
all the batches, release rates were significantly different (p<0.05). 
  
Table 5: Some release parameters of artesunate matrix tablets in 0.1N NaOH 
Batch  T30%* (h) T50%* (h) T70%* (h) Cmax** (%) 
A 1.00  3.00  8.00 70 
B 2.00  5.50 10.00 71 
C 3.00  7.50 - 63 
D 6.26 11.00 18.00 73 
*T30%, T50% and T70%, are the times required for 30%, 50 % and 70 % of artesunate to be released respectively, **Cmax is the maximum drug 
concentration obtained for each batch 
 
Table 6: Release kinetics model of artesunate from the different matrices 
Batch  Zero-order First order Higuchi Korsmeyer 
 R2 K (h-1) R2 K (h-1) R2 K (h-1) R2 N 
A -0.1666 41.2 0.4732 0.0241 0.7016 26.365 0.4492 1.0092 
B  0.8134 38.8 0.9340 0.0520 0.9060 23.318 0.6529 1.2126 
C  0.8991 30.2 0.9481 0.0461 0.9380 20.077 0.7449 1.2853 
D  0.9097 22.3 0.8801 0.3080 0.8974 14.165 0.7086 1.1391 
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Fig. 1: Release profile of artesunate in 0.1N NaOH 
 
n = 3; the fig. was plotted from the average values of three (3) 
determinations of cumulative percentage of drug released 
Batches B and C obeyed first-order kinetics in term of release. Batch 
A following Higuchi model while batch D followed of zero order. 
Analysis using the Ritzer-Peppas model indicated that they all had 
complex release mechanism as the n value in each batch was above 
0.89. The mechanism of release was the same probably because they 
all had HPMC as the binder. 
 
Table 7: Parameters determined from in vivo release studies 
Batch  TCmaxa (h) T1/2b (h) AUCc (μg/ml/h) 
Control 1.00 1.21  96.00 
A 1.00 1.16  88.00 
B 2.00 1.22 103.00 
C 1.00 0.65  64.56 
D 2.00 0.99  76.19 
Mean  - 1.05 - 
aTime taken to obtain maximum concentration (TCmax), bhalf-life (T1/2) and carea under curve (AUC) were derived from in vivo release plots 
 
 
Fig. 2: Plots of the amount of artesunate released from the different matrices per unit time 
 
n = 3; the fig. was plotted from the average values of three (3) 
determinations of the amount of drug released per unit time. 
The values of Tcmax in the in vivo study indicated that all the batches had 
a maximum concentration within the first 1 h except batch B that was 
at 2 h. The values were in close range. From the result, the sustained 
release properties of the batches were not completely reflected. This 
could be attributed to the fact that the tablets had to be crushed and 
suspended in water prior to administration thereby countering the 
effect of the binder and more so as HPMC is soluble in water. The t1/2 
value of 1.05 h also supports the reason for subjecting artesunate to 
sustained release delivery. The AUC values indicate that they were in a 
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close range. As shown in fig. 2, there was an increase in the amount of 
artesunate after the fourth hour. This could be attributed to the fact 
that artesunate in the living system may have produced metabolites 
that absorb at the same wavelength of artesunate. 
CONCLUSION 
The development of drug substance cannot be said to be complete 
until an appropriate assay method both in vitro and in vivo have 
evolved. The identities of different drug substances are of 
paramount importance in an attempt to develop an assay method. 
The solubility of artesunate generally varies with media used. Many 
drugs may exist in more than one polymorphs and that could 
account for variation in solubility of artesunate in SIF. The 
wavelength of a maximum of absorption of the two types of 
artesunate was 287 nm and 288 nm indicating the presence of the 
same chromophore but possibly different crystal form. 
The release kinetics obtained showed that zero order, first order 
and Higuchi model kinetics were involved in the release of 
artesunate from the tablet. The mechanism of release was shown 
to be complex. 
In vivo studies showed the high release of artesunate and biological 
half-life of artesunate is 1.05 h. 
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